BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PolyPid Ltd. and MIS Implants Technologies Announce Strategic Partnership to Provide Innovative Drug Delivery Product for Dental Applications


3/4/2013 12:03:27 PM

Petach Tikva and Bar-Lev Industrial Park, Israel, March 4, 2013. PolyPid Ltd., a developer of unique innovative drug carriers, and MIS Implants Technologies Ltd., a leading manufacturer of dental implants, today announced a strategic partnership to provide an innovative drug delivery product for dental applications. The unique product, to be developed by PolyPid, will be based on BonyPidTM – PolyPid's product family that can also treat specific dental problems requiring local, prolonged and constant controlled release of drugs, allowing quick and optimal healing of specific dental morbidities, such as periodontitis. The new dental product will be marketed and distributed exclusively by MIS Implants Technologies.

A BonyPidTM-based product, designed to treat bone contaminations or infections caused during bone recovery of severe open long-bone fractures, was recently tested successfully in a first-in-man clinical trial. Due to the fact that there are some similar limitations in both orthopedic and dental procedures, PolyPid and MIS decided to implement the BonyPidTM technology concept for specific dental indications.

The new BonyPid™ dental product will be based on synthetic particles coated with a micro-layer, based on PolyPid's nanotechnology drug delivery platform. The fully biodegradable coating will release drugs at an accurate dosage directly into the affected area, over a prolonged period and at a pre-planned rate. The product is due out in the first quarter of 2015.

"Nano-therapeutics for dental problems is currently a hot issue and a source of hope for those who suffer from certain dental problems, as well as a solution for dentists coping with various morbidities of their patients," said Dr. Noam Emanuel, PolyPid's Chief Technology Officer. "The new product will meet some major challenges in this area."

"This is an important milestone in PolyPid's business development, reflecting our strategy to expand PolyPid's platform applications through cooperation with leading partners in various spheres," said Amir Weisberg, PolyPid's CEO. "We have plans for more innovative products and we are now exploring additional opportunities for cooperation with leading companies in various medical fields."

"As a company that has operated for many years at the technological forefront of the dental implants industry, we are committed to continuous research and development of new progressive products and technologies to support the diverse challenges faced by dentistry," said Idan Kleifeld, MIS's CEO. "PolyPid is a natural partner to our efforts and their technology leads to innovative therapies and solutions."

PolyPid's platform (also named PolyPid technology), is a new, unique and pioneering family of drug carriers, based on an innovative fusion between polymers and lipid-based systems. PolyPid nanotechnology enables determining in advance the desired release rate of the drug, as well as the optimal duration, which may last up to several months. The revolutionary platform is protected by a series of strong patents, and is adaptable to a wide variety of drugs: small molecules such as antibiotics and anti-inflammatory drugs, peptides, proteins and also can be used for the administration of drugs based on nucleic acids (DNA and RNA).

About PolyPid Ltd.

Founded in 2008 and located in Israel, PolyPid Ltd. is a privately held, development stage company that has developed a platform enabling a controlled and prolonged release of any active pharmaceutical ingredient (API). PolyPid’s nanotechnology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. PolyPid's technology allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. The flexibility of this innovative technology enables local administration of compounds across numerous therapeutic classes for several applications. PolyPid Ltd. is owned by its founders, private investors and Xenia Venture Capital. For more information about PolyPid Ltd., visit www.polypid.com

About MIS Implants Technologies Ltd.

Established in 1995, MIS Implants Technologies Ltd. is a global leader in the development, production and marketing of advanced products and innovative solutions aimed to simplify dental implantology. With a state of the art production facility, MIS offers a comprehensive range of cutting-edge dental implants and superstructures as well as a wide range of solutions for oral restoration and health. The company's products are being distributed in 70 countries through its well established global distribution network, represented by MIS's loyal partners and subsidiaries worldwide. For more information about MIS Implants Technologies Ltd., visit www.mis-implants.com

Contact:

David Kanaan

Kanaan Public Relations

Tel.: +972-54-4255307

e-mail: David@KanaanPR.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES